Erasca Entered into a Clinical Trial Collaboration and Supply Agreement with Eli Lilly to Evaluate ERAS-007 and Erbitux (cetuximab) for Metastatic Colorectal Cancer
Shots:
- The companies collaborated to support an ongoing P-Ib/II (HERKULES-3) trial to evaluate ERAS-007 (ERK1/2 inhibitor) in multiple combinations including Braftovi (BRAF inhibitor) & cetuximab for the treatment of BRAF V600E-mutant mCRC
- Erasca will sponsor the study & Lilly will be responsible to supply cetuximab at no cost. Additionally, both companies will form a joint committee to review the clinical trial results
- The preclinical data helps to supports ERAS-007 to block MAPK pathway reactivation & limit resistance to encorafenib & cetuximab. Additionally, encorafenib + cetuximab can significantly improve OS, 20% experience an ORR & 50% of responses lasted ≥4mos.
Ref: Globe Newswire | Image: Globe Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
